453 results
8-K
EX-99.1
JAZZ
Jazz Pharmaceuticals plc
1 May 24
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results
4:06pm
AG products and increased Xywav and Epidiolex/Epidyolex net product sales.
Operating Expenses and Effective Tax Rate
Three Months Ended
March 31 … and development
% of total revenues
Acquired in-process research and development
Income tax expense (benefit)1
Effective tax rate 1
1.The GAAP income tax
8-K
EX-99.1
uxrsspj54t8j3
28 Feb 24
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
sw2mt8h grhyt6kmy
21 Feb 24
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
7:46am
8-K
EX-10.1
hdu51hv91km0r0ag19w
25 Jan 24
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99.1
8s3pozwictzwoenzo8jf
8 Jan 24
Results of Operations and Financial Condition
7:45am
8-K
EX-99.1
snwp1
8 Nov 23
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:07pm